00:27 , Jul 11, 2019 |  BC Extra  |  Company News

July 10 Company Quick Takes: I-Mab licenses MacroGenics mAb; plus Mirati-Novartis, Jazz-Redx, Sanofi, Horizon and more

I-Mab gains China rights to enoblituzumab I-Mab Biopharma (Shanghai, China) gained exclusive rights to enoblituzumab from MacroGenics Inc. (NASDAQ:MGNX) in China, Hong Kong, Macao and Taiwan for $15 million up front. MacroGenics is eligible for...
21:58 , May 24, 2019 |  BioCentury  |  Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

FDA's ODAC may have given the thumbs down to Daiichi’s quizartinib, but a stocked pipeline and another ongoing trial of the candidate suggest it’s more of a hiccup than a hurdle in the Japanese pharma’s...
04:45 , Feb 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Solid checkpoint for CARs

PD-L1 family member B7-H3 could put CAR T cells in play for a slew of difficult-to-treat solid tumors, including pediatric cancers that lack targeted therapies, according to a pair of preclinical studies published this year....
19:35 , Feb 13, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Bone cancer; sarcoma; brain cancer Mouse studies suggest CAR T cells targeting B7-H3 could help treat pediatric osteosarcoma, Ewing sarcoma and brain cancer. In tumor samples from 388 patients with pediatric solid tumors and...
00:35 , Feb 1, 2019 |  BC Innovations  |  Tools & Techniques

TMB needs company

Tumor mutation burden is looking less like a magic bullet and more like just one of at least three variables that could jointly predict responses to checkpoint inhibitors. Combining TMB measurements with markers of T...
21:07 , Dec 14, 2018 |  BC Week In Review  |  Clinical News

FDA places hold on Phase I trials of MacroGenics' bispecific molecule due to hepatic events

MacroGenics Inc. (NASDAQ: MGNX) said FDA placed a partial clinical hold on two Phase I trials of MGD009 to treat cancer after the company reported hepatic adverse events in one of the trials that is...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
17:22 , Sep 28, 2018 |  BC Week In Review  |  Financial News

First-day pop for Y-mAbs after upsized $110M IPO

Cancer company Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) gained $8 (50%) to $24 on Sept. 21 after raising $110.4 million through the sale of 6.9 million shares at $16 in an IPO. BofA Merrill Lynch, Cowen, Canaccord...
23:53 , Sep 20, 2018 |  BC Extra  |  Financial News

First-day pop for Y-mAbs after upsized $96M IPO

Cancer company Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) gained $8 (50%) to $24 on Friday after raising $96 million through the sale of 6 million shares at $16 in an IPO. BofA Merrill Lynch, Cowen, Canaccord Genuity...
18:38 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Y-mAbs aims for $92M IPO

Y-mAbs Therapeutics Inc. (New York, N.Y.) filed to raise up to $92 million on Aug. 24 in an IPO on NASDAQ underwritten by BofA Merrill Lynch, Cowen, Canaccord Genuity and BTIG. Y-mAbs hopes to submit...